Annexin Pharmaceuticals completes enrollment in NEXUS trial of vanexin

• Annexin Pharmaceuticals completed enrollment in its NEXUS vanexin study, recruiting 12 patients: nine with retinal vein occlusion and three with diabetic retinopathy.
• Results are due in November 2026 for diabetic retinopathy patients and December 2026 for the expanded retinal vein occlusion cohort.
• The study will finish in the first quarter of 2027, with topline results expected by quarter-end.
• An FDA meeting expected in early 2027 will address Phase 2b and Phase 3 study design, including vanexin treatment following anti-VEGF therapy.
• Global or regional licensing discussions aim to secure a Phase 2b partner; timing for a potential agreement remains uncertain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexin Pharmaceuticals AB (publ) published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.